Elite Pharmaceuticals, Inc.
ELTP
Rank in Stocks
#15569
Elite Pharmaceuticals, Inc. (ELTP) is a specialized pharmaceutical company... Elite Pharmaceuticals, Inc. (ELTP) is a specialized pharmaceutical company focused on the creation and manufacturing of generic medications, as well as oral, controlled-release drug formulations. Its business activities are primarily divided into two segments: Abbreviated New Drug Applications (ANDAs) for generic products and New Drug Applications (NDAs) for branded pharmaceuticals. The company's extensive product line includes drugs that it either owns, licenses, or produces through contract manufacturing. This portfolio features a variety of generic and oral-dose pharmaceutical products designed to address diverse medical needs. For instance, it offers Phentermine HCl 37.5mg tablets, marketed under the Adipex-P brand, and Phendimetrazine Tartrate 35mg tablets, known as Bontril, both utilized in bariatric medicine. Its offerings also extend to Naltrexone HCl 50mg tablets (Revia brand) for pain management, and Isradipine 2.5mg and 5mg capsules for cardiovascular conditions. Elite Pharmaceuticals further supplies various strengths of Oxycodone HCl immediate release tablets (5mg, 10mg, 15mg, 20mg, and 30mg) under the Roxycodone brand for pain relief, as well as Trimipramine Maleate Immediate Release antidepressant capsules (Surmontil brand). For central nervous system disorders, the company provides Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets, commonly associated with the Adderall brand. Additionally, its products include Dantrolene Sodium capsules (Dantrium brand) for muscle relaxation, SequestOX (an immediate-release Oxycodone formulation combined with Naltrexone), Loxapine Succinate capsules (Loxapine brand) for antipsychotic treatment, and a combination of Acetaminophen and Codeine Phosphate for managing mild to moderate pain, alongside various antibiotic products. Beyond its own product portfolio, Elite Pharmaceuticals also undertakes contract manufacturing of controlled-release products for external parties, covering therapeutic areas such as pain, allergies, bariatrics, and infections. The company is actively engaged in developing a new generation of opioid products specifically engineered to deter abuse. Established in 1997, Elite Pharmaceuticals, Inc. maintains its corporate headquarters in Northvale, New Jersey.
Share Price
$0.237
Last synced: 2026-11-09
Market Cap
$255.28M
Change (1 day)
-1.25%
Change (1 year)
-63.31%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Elite Pharmaceuticals, Inc. (ELTP)
Category
Healthcare
EPS for Elite Pharmaceuticals, Inc. (ELTP)
EPS as of June 2026 TTM: $0.05
According to Elite Pharmaceuticals, Inc.'s latest financial reports, its current EPS (TTM) is $0.05. At the end of 2025 the company had an EPS of 0.00, a decrease compared to its 2024 EPS of $0.02.
EPS history for Elite Pharmaceuticals, Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.05 | -120.20% |
| 2025 | 0.00 | -120.20% |
| 2024 | $0.02 | -99.54% |
| 2023 | $4.35 | 49,331.82% |
| 2022 | $0.01 | 62.96% |
| 2021 | $0.01 | -300.00% |
| 2020 | 0.00 | -76.32% |
| 2019 | $-0.01 | 147.83% |
| 2018 | 0.00 | -115.33% |
| 2017 | $0.03 | -3,100.00% |
| 2016 | 0.00 | -102.00% |
| 2015 | $0.05 | -123.81% |
| 2014 | $-0.21 | -4,983.72% |
| 2013 | 0.00 | -107.40% |
| 2012 | $-0.06 | -58.50% |
| 2011 | $-0.14 | 27.27% |
| 2010 | $-0.11 | -47.62% |
| 2009 | $-0.21 | -67.19% |
| 2008 | $-0.64 | 6.67% |
| 2007 | $-0.60 | 62.16% |
| 2006 | $-0.37 | -19.57% |
| 2005 | $-0.46 | -20.69% |
| 2004 | $-0.58 | 45.00% |
| 2003 | $-0.40 | 110.53% |
| 2002 | $-0.19 | -87.58% |
| 2001 | $-1.53 | 325.00% |
| 2000 | $-0.36 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $6.50 | 12,902.80% |
DE
|
|
| $6.08 | 12,055.20% |
DE
|
|
| $1.55 | 3,001.20% |
JP
|
|
| $3.66 | 7,220.00% |
CH
|
|
| $0.45 | 800.00% |
IL
|
Questions about Elite Pharmaceuticals, Inc.'s earnings per share (EPS)
What is Elite Pharmaceuticals, Inc.'s earnings per share (EPS)?
Elite Pharmaceuticals, Inc.'s earnings per share (EPS) over the last twelve months is $0.05, as of Jun 2026.
What was Elite Pharmaceuticals, Inc.'s earnings per share (EPS) in 2025?
In 2025, Elite Pharmaceuticals, Inc.'s earnings per share (EPS) was 0.00, compared with $0.02 in 2024.
How has Elite Pharmaceuticals, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Elite Pharmaceuticals, Inc.'s earnings per share (EPS) was highest in 2023 ($4.35) and lowest in 2025 (0.00).
How does Elite Pharmaceuticals, Inc.'s earnings per share (EPS) compare with similar companies?
Elite Pharmaceuticals, Inc.'s earnings per share (EPS) ($0.05) is lower than that of all 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.50.